Surrozen (SRZN) Share-based Compensation (2020 - 2026)
Surrozen (SRZN) posted quarterly Share-based Compensation of $37.3 million for Q1 2026, up 4372.42% year-over-year from $834000.0 in Q1 2025, and up 3622.55% quarter-over-quarter from $1.0 million in Q4 2025.
Analysis
Surrozen (SRZN) Share-based Compensation (2020 - 2026) Analysis & Trends
Surrozen's Share-based Compensation history runs 7 years deep, the most recent figure standing at $37.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 4372.42% year-over-year to $37.3 million; the TTM figure through Mar 2026 stood at $37.3 million (up 852.02% YoY), while the FY2025 annual figure was $8.1 million, up 96.89% from the prior year.
- Share-based Compensation for Q1 2026 stood at $37.3 million, up from $1.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $37.3 million in Q1 2026, with the low at $834000.0 in Q1 2025.
- The 5-year median for Share-based Compensation is $1.0 million (2024), against an average of $3.2 million.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation fell 24.14% in 2023, then jumped 4372.42% in 2026.
- Surrozen's Share-based Compensation stood at $1.5 million in 2022, then dropped by 24.14% to $1.2 million in 2023, then decreased by 23.21% to $900000.0 in 2024, then advanced by 11.33% to $1.0 million in 2025, then surged by 3622.55% to $37.3 million in 2026.
- Business Quant data shows SRZN's Share-based Compensation at $37.3 million in Q1 2026, $1.0 million in Q4 2025, and $1.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | 35.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35.30 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 923,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | 4.75 Mn |
| Jun 30, 2023 | 5.00 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 979,000.00 |
| Mar 31, 2022 | 916,000.00 |
| Dec 31, 2021 | 693,000.00 |
| Sep 30, 2021 | 1.70 Mn |